Cargando…

Step Length Is a Promising Progression Marker in Parkinson’s Disease

Current research on Parkinson’s disease (PD) is increasingly concerned with the identification of objective and specific markers to make reliable statements about the effect of therapy and disease progression. Parameters from inertial measurement units (IMUs) are objective and accurate, and thus an...

Descripción completa

Detalles Bibliográficos
Autores principales: Welzel, Julius, Wendtland, David, Warmerdam, Elke, Romijnders, Robbin, Elshehabi, Morad, Geritz, Johanna, Berg, Daniela, Hansen, Clint, Maetzler, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037757/
https://www.ncbi.nlm.nih.gov/pubmed/33805914
http://dx.doi.org/10.3390/s21072292
_version_ 1783677218235351040
author Welzel, Julius
Wendtland, David
Warmerdam, Elke
Romijnders, Robbin
Elshehabi, Morad
Geritz, Johanna
Berg, Daniela
Hansen, Clint
Maetzler, Walter
author_facet Welzel, Julius
Wendtland, David
Warmerdam, Elke
Romijnders, Robbin
Elshehabi, Morad
Geritz, Johanna
Berg, Daniela
Hansen, Clint
Maetzler, Walter
author_sort Welzel, Julius
collection PubMed
description Current research on Parkinson’s disease (PD) is increasingly concerned with the identification of objective and specific markers to make reliable statements about the effect of therapy and disease progression. Parameters from inertial measurement units (IMUs) are objective and accurate, and thus an interesting option to be included in the regular assessment of these patients. In this study, 68 patients with PD (PwP) in Hoehn and Yahr (H&Y) stages 1–4 were assessed with two gait tasks—20 m straight walk and circular walk—using IMUs. In an ANCOVA model, we found a significant and large effect of the H&Y scores on step length in both tasks, and only a minor effect on step time. This study provides evidence that from the two potentially most important gait parameters currently accessible with wearable technology under supervised assessment strategies, step length changes substantially over the course of PD, while step time shows surprisingly little change in the progression of PD. These results show the importance of carefully evaluating quantitative gait parameters to make assumptions about disease progression, and the potential of the granular evaluation of symptoms such as gait deficits when monitoring chronic progressive diseases such as PD.
format Online
Article
Text
id pubmed-8037757
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80377572021-04-12 Step Length Is a Promising Progression Marker in Parkinson’s Disease Welzel, Julius Wendtland, David Warmerdam, Elke Romijnders, Robbin Elshehabi, Morad Geritz, Johanna Berg, Daniela Hansen, Clint Maetzler, Walter Sensors (Basel) Brief Report Current research on Parkinson’s disease (PD) is increasingly concerned with the identification of objective and specific markers to make reliable statements about the effect of therapy and disease progression. Parameters from inertial measurement units (IMUs) are objective and accurate, and thus an interesting option to be included in the regular assessment of these patients. In this study, 68 patients with PD (PwP) in Hoehn and Yahr (H&Y) stages 1–4 were assessed with two gait tasks—20 m straight walk and circular walk—using IMUs. In an ANCOVA model, we found a significant and large effect of the H&Y scores on step length in both tasks, and only a minor effect on step time. This study provides evidence that from the two potentially most important gait parameters currently accessible with wearable technology under supervised assessment strategies, step length changes substantially over the course of PD, while step time shows surprisingly little change in the progression of PD. These results show the importance of carefully evaluating quantitative gait parameters to make assumptions about disease progression, and the potential of the granular evaluation of symptoms such as gait deficits when monitoring chronic progressive diseases such as PD. MDPI 2021-03-25 /pmc/articles/PMC8037757/ /pubmed/33805914 http://dx.doi.org/10.3390/s21072292 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Brief Report
Welzel, Julius
Wendtland, David
Warmerdam, Elke
Romijnders, Robbin
Elshehabi, Morad
Geritz, Johanna
Berg, Daniela
Hansen, Clint
Maetzler, Walter
Step Length Is a Promising Progression Marker in Parkinson’s Disease
title Step Length Is a Promising Progression Marker in Parkinson’s Disease
title_full Step Length Is a Promising Progression Marker in Parkinson’s Disease
title_fullStr Step Length Is a Promising Progression Marker in Parkinson’s Disease
title_full_unstemmed Step Length Is a Promising Progression Marker in Parkinson’s Disease
title_short Step Length Is a Promising Progression Marker in Parkinson’s Disease
title_sort step length is a promising progression marker in parkinson’s disease
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037757/
https://www.ncbi.nlm.nih.gov/pubmed/33805914
http://dx.doi.org/10.3390/s21072292
work_keys_str_mv AT welzeljulius steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT wendtlanddavid steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT warmerdamelke steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT romijndersrobbin steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT elshehabimorad steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT geritzjohanna steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT bergdaniela steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT hansenclint steplengthisapromisingprogressionmarkerinparkinsonsdisease
AT maetzlerwalter steplengthisapromisingprogressionmarkerinparkinsonsdisease